University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 4P-07-3

A Phase II Trial of a Combination Herbal Therapy for Men with Biochemical Recurrence of Prostate Cancer After Initial Local Therapy.

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Other
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Tanya Dorff, M.D.
Other Trial Staff:  Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Kristy Sartor Massopust, Coordinator, Laurie De Oliveira, Coordinator, Ernesto Duverger, D.M.

Staff may log in to see study documents.

You may participate in this study if:
1Men 18 y/o and above.
2Histologically documented adenocarcinoma of the prostate.
3Initial treatment with radical prostatectomy or external beam radiation.
4Neoadjuvant / Adjuvant Androgen Deprivation therapy allowable, provided it was for a maximum of 9 months, with the last dose of medication at least 12 months previously.
5Neoadjuvant or adjuvant chemotherapy allowable, provided it was for a maximum of 6 months, with the last dose of medication at least 12 months previously.
6Adjuvant radiation after radical prostatectomy is allowed, provided at least 6 months have elapsed between completion of radiation and enrollment in study.
7PSA recurrence, with a rising PSA, as defined by:
8Post Radiation Therapy: absolute PSA >2.0 ng/mL, PSA nadir <4 ng/mL after radiation, Absolute rise of at least 0.5 ng/mL total, Two sequential increases in PSA, separated by at least 2 weeks.
9Post Prostatectomy: absolute PSA >2.0 ng/mL, PSA nadir <0.3 after surgery, absolute rise of at least 2 ng/mL total, two sequential increases in PSA separated by at least 2 weeks.
10PSA Doubling Time (PSA DT) more than 3 months and less than 18 months. PSA DT to be calculated using the web-based calculator at ttp:// with the following constraints: ?At least 3 values, but no more than 6, ?All values must be >0.2, ?Values must be separated by at least 2 months.
11No radiographically evident bony or soft tissue metastases.
12Documented discussion between subject and physician about the option to pursue hormone therapy and/or salvage local therapy rather than enroll in this study.
13ECOG Performance Status 0-2.
14Life expectancy > 12 months.
15Adequate hepatic function (AST, ALT & bilirubin less than or equal to 1.5 x ULN).
16Adequate renal function (eGFR by Cockcroft-Gault or comparable calculation 50 ml/min or greater).
17Willing to discontinue all nutritional supplements and 5-alpha reductase inhibitors (finasteride, dutasteride) for the duration of study treatment, unless the medication is being used to control symptoms of BPH, and the patient has been taking the medication for more than 6 weeks.
18Willing to discontinue all weight control medications for the duration of study treatment.
19Signed Informed Consent, including HIPAA authorization.

You may not participate in this study if:
1Atypical prostate carcinoma histology (ex: small cell, adenoid cystic).
2Evidence of bony or soft tissue metastatic disease on CT or bone scan.
3Prior treatment with androgen deprivation therapy for PSA recurrence, including GnRH analogue (leuprolide, goserelin) or anti-androgen (bicalutamide, flutamide, or nilutamide).
4Other invasive malignancy within prior 3 years, except for fully treated basal cell or squamous cell carcinoma of the skin.
5Full-dose anticoagulation therapy (warfarin or low molecular weight heparin) or antiplatelet therapy (clopidogrel or ticlopidine), with the exception of low-dose aspirin therapy (81 mg).
6Significant cardiac disease, included but not limited to angina, myocardial infarction, cardiomyopathy, congestive heart failure, and coronary artery disease which has required bypass surgery, angioplasty or stent placement.
7Significant uncontrolled comorbid condition which, in the opinion of the treating physician would compromise the subject’s ability to comply with protocol requirements, or would pose undue risk for experiencing adverse events.

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.